Recent Company News

• 12:30 AM ET Jan 02, 2026
  

  Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations

• 04:02 AM ET Dec 09, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 03:54 AM ET Dec 09, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (77 total)

• 02:49 AM ET Dec 09, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:13 AM ET Dec 09, 2025
  

  Novo Holdings selling up to ~9.4M shares in Evotec -- wires (8-Dec, post European market close) (€5.50, 0.00)

• 01:28 AM ET Dec 08, 2025
  

  Evotec confirms completes the sale of Just - Evotec Biologics' Toulouse site to Sandoz (€5.43, 0.00)

• 01:05 AM ET Dec 08, 2025
  

  Sandoz Group completes acquisition of Just-Evotec Biologics EU SAS (JEB SAS) from Evotec (CHF 57.70, 0.00)

• 02:50 AM ET Dec 04, 2025
  

  Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome

• 02:35 AM ET Dec 04, 2025
  

  Evotec notes Bayer's trial initiation announcement; expects milestone payment upon first dosing of first study participant in early 2026 (€5.51, 0.00)

• 02:31 AM ET Dec 04, 2025
  

  Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome (€34.44, 0.00)